Drugs / IVAC MUTANOME
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02035956 | Dec 2013 → Feb 2017 | melanoma | BioNTech RNA Pharmaceuticals GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVAC MUTANOME | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02035956 ↗ |
| Modality | Vaccine | “IVAC MUTANOME is a poly-neo-epitopic coding RNA vaccine” NCT02035956 ↗ |
| Route | Other | “Vaccines will be administered intra-nodally.” NCT02035956 ↗ |